Chemopreventive mechanisms of α-keto acid metabolites of naturally occurring organoselenium compounds.
Previous studies on the chemopreventive mechanisms of dietary selenium have focused on its incorporation into antioxidative selenoproteins, such as glutathione peroxidase and thioredoxin reductase. Several studies, however, have revealed that dietary selenium in the form of L-selenomethionine and the 21st amino acid, selenocysteine, also have intrinsic anti-cancer properties. Biochemical mechanisms previously investigated to contribute to their anticancer effects involve β- and γ-lyase reactions. Some pyridoxal 5'-phosphate (PLP)-containing enzymes can catalyze a β-lyase reaction with Se-methyl-L-selenocysteine (MSC) generating pyruvate and ammonia. Other PLP-enzymes can catalyze a γ-lyase reaction with L-selenomethionine (SM) generating α-ketobutyrate and ammonia. In both cases, a purported third product is methylselenol (CH(3)SeH). Although not directly quantifiable, as a result of its extreme hydrophobicity and high vapor pressure, CH(3)SeH has been indirectly observed to act through the alteration of protein-sulfhydryl moieties on redox-responsive signal and transcription factors, thereby maintaining a non-proliferative intracellular environment. We have considered the possibility that α-keto acid analogues of MSC (i.e., methylselenopyruvate; MSP) and SM (i.e., α-keto-γ-methylselenobutyrate; KMSB), generated via a transamination and/or L-amino acid oxidase reaction may also be chemoprotective. Indeed, these compounds were shown to increase the level of histone-H3 acetylation in human prostate and colon cancer cells. MSP and KMSB structurally resemble butyrate, an inhibitor of several histone deacetylases. Thus, the seleno α-keto acid metabolites of MSC and SM, along with CH(3)SeH derived from β- and γ-lyase reactions, may be potential direct-acting metabolites of organoselenium that lead to de-repression of silenced tumor suppressor proteins and/or regulation of genes and signaling molecules.
Pinto
John T
JT
Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, 10595, USA. John_pinto@nymc.edu
Lee
Jeong-In
JI
Sinha
Raghu
R
MacEwan
Melanie E
ME
Cooper
Arthur J L
AJ
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D007651:Keto Acids / Q000737:chemistry / Q000378:metabolism*; D016566:Organoselenium Compounds / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology
D000970:Antineoplastic Agents; D007651:Keto Acids; D016566:Organoselenium Compounds
Cancer Res. 2008 Dec 15;68(24):10290-9
19074897
Nat Med. 2005 Jan;11(1):71-6
15619634
Int J Cancer. 2007 Apr 1;120(7):1410-7
17205524
Cancer Res. 2000 Jun 1;60(11):2882-6
10850432
Eur J Biochem. 2001 Jun;268(11):3346-53
11389738
J Cell Biochem. 2009 Jul 1;107(4):600-8
19459166
Am J Transl Res. 2009 May 25;1(4):341-51
19956446
Cancer Res. 2002 May 1;62(9):2540-5
11980647
Mol Interv. 2009 Feb;9(1):18-21
19299660
Carcinogenesis. 2009 Aug;30(8):1416-23
19528666
JAMA. 1996 Dec 25;276(24):1957-63
8971064
Neurochem Int. 2004 Jun;44(8):557-77
15016471
Mol Cancer Ther. 2002 Oct;1(12):1059-66
12481429
Br J Cancer. 2004 Jul 19;91(2):195-9
15213714
J Urol. 2001 Oct;166(4):1311-5
11547064
Mini Rev Med Chem. 2008 Sep;8(10):1020-31
18782054
Expert Opin Ther Targets. 2008 Nov;12(11):1457-67
18851700
Br J Nutr. 2008 Jun;99(6):1190-8
18062829
Carcinogenesis. 2008 May;29(5):1005-12
18310093
Nat Rev Drug Discov. 2006 Sep;5(9):769-84
16955068
Cancer Res. 2009 Feb 1;69(3):958-66
19176386
Nutr Cancer. 2008;60(2):267-75
18444160
Eur J Biochem. 1976 Mar 16;63(1):163-73
1261544
Am J Transl Res. 2009;1(1):62-71
19966939
Adv Enzymol Relat Areas Mol Biol. 1998;72:199-238
9559054
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):673-8
15637150
Curr Cancer Drug Targets. 2004 Feb;4(1):13-28
14965264
Antioxid Redox Signal. 2007 Jan;9(1):25-47
17115886
Environ Health Perspect. 2009 Sep;117(9):1409-13
19750106
Nutr Cancer. 2001;40(1):34-41
11799920
Br J Nutr. 2004 Jan;91(1):11-28
14748935
J Clin Oncol. 2009 Nov 10;27(32):5459-68
19826124
Anal Biochem. 1968 Nov;26(2):313-9
4394442
Arch Biochem Biophys. 2008 Jun 1;474(1):72-81
18342615
BJU Int. 2003 May;91(7):608-12
12699469
Carcinogenesis. 2008 Sep;29(9):1816-24
18628250
Environ Mol Mutagen. 2009 Apr;50(3):213-21
19197985
Blood. 2007 Jul 1;110(1):220-7
17356132
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9
10954755
Clin Ter. 2008 Sep-Oct;159(5):347-60
18998037
Biol Trace Elem Res. 2005 Winter;108(1-3):245-57
16327076
Nat Rev Urol. 2009 Aug;6(8):429-39
19657377
Int J Oncol. 2008 Aug;33(2):375-80
18636159
Curr Cancer Drug Targets. 2004 Mar;4(2):205-18
15032670
Ann N Y Acad Sci. 1990;585:118-27
2192607
Enzymologia. 1960 Sep 1;22:161-73
13691729
J Immunol. 2004 Oct 1;173(7):4561-7
15383589
Singapore Med J. 2009 Mar;50(3):265-9
19352569
Breast Cancer Res. 2005;7(5):R699-707
16168115
JAMA. 2009 Jan 7;301(1):39-51
19066370
Biochem J. 2000 Aug 15;350 Pt 1:199-205
10926844
Biol Chem. 2007 Oct;388(10):997-1006
17937613
Antioxid Redox Signal. 2007 Jul;9(7):775-806
17508906
J Biol Chem. 2002 May 24;277(21):19080-6
11907037
Mol Cancer Res. 2007 Oct;5(10):981-9
17951399
Arch Biochem Biophys. 1967 Oct;122(1):164-73
6076213
Cancer Res. 2004 Dec 15;64(24):9209-16
15604294
Nutr Cancer. 2009;61(3):285-6
19373601
Chem Res Toxicol. 2002 Dec;15(12):1610-8
12482244
Int J Cancer. 2009 Aug 15;125(4):774-82
19384952
Anticancer Agents Med Chem. 2008 Aug;8(6):598-602
18690824
Mol Carcinog. 2002 Jul;34(3):113-20
12112305
Toxicol Appl Pharmacol. 2008 Feb 15;227(1):76-83
18035386
Mol Cancer Ther. 2002 Oct;1(12):1079-87
12481431
Biochem Mol Biol Int. 1994 Jan;32(1):79-86
8012292
FASEB J. 2009 Aug;23(8):2514-20
19276171
Carcinogenesis. 1999 Sep;20(9):1657-66
10469608
Bioorg Med Chem. 2005 Nov 1;13(21):6070-82
16006131
J Natl Cancer Inst. 2005 Jan 19;97(2):94-102
15657339
Carcinogenesis. 2009 Nov;30(11):1941-8
19759193
J Nutr. 2009 Sep;139(9):1613-8
19625696
Urol Oncol. 2003 Jan-Feb;21(1):59-65
12684129
Cancer Res. 2004 Aug 15;64(16):5767-74
15313918
Oncogene. 2007 Aug 13;26(37):5541-52
17694093
Biochem Pharmacol. 2005 Jan 15;69(2):209-20
15627473
Nutr Cancer. 2001;40(1):64-73
11799926
Mol Nutr Food Res. 2008 Nov;52(11):1281-8
18686292
J Pharmacol Exp Ther. 2000 Aug;294(2):753-61
10900257
J Toxicol Sci. 2009 Apr;34(2):191-200
19336976
J Nutr. 1998 Nov;128(11):1845-54
9808633
Cancer Prev Res (Phila). 2009 Jul;2(7):683-93
19584079
Cancer Lett. 2009 Aug 8;280(2):125-33
19359091
J Biol Chem. 1986 Nov 25;261(33):15529-37
3782077
J Natl Cancer Inst. 1996 Nov 20;88(22):1623-34
8931606
EMBO J. 2005 Mar 9;24(5):1021-32
15692560
Leukemia. 2009 May;23(5):952-60
19436310
Cancer Res. 2002 Dec 1;62(23):7050-8
12460926
Chem Res Toxicol. 2009 Nov;22(11):1795-801
19715347
J Biol Chem. 1952 May;197(1):319-30
12981062
Adv Exp Med Biol. 2008;615:261-98
18437899